Ron receptor tyrosine kinase activation confers resistance to tamoxifen in breast cancer cell lines

Neoplasia

Volumn 12, Issue 8, 2010, Pages 650-658

  McClaine, Rebecca J ^a   Marshall, Aaron M ^a   Wagh, Purnima K ^a   Waltz, Susan E ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; ESTROGEN RECEPTOR; HEPATOCYTE GROWTH FACTOR LIKE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN TYROSINE KINASE; RON RECEPTOR TYROSINE KINASE; SERINE; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER RESISTANCE; CELL STRAIN MCF 7; CELL SURVIVAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG SPECIFICITY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 77956039906     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.10476     Document Type: Article

References (38)

1. Clarke R, Leonessa F, Welch JN, and Skaar TC (2001). Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 53, 25-71.
2. Yu J, Yu J, Cordero KE, Johnson MD, Ghosh D, Rae JM, Chinnaiyan AM, and Lippman ME (2008). A transcriptional fingerprint of estrogen in human breast cancer predicts patient survival. Neoplasia 10, 79-88.
3. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, and Schiff R (2003). Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95, 353-361.
4. Keeton EK and Brown M (2005). Cell cycle progression stimulated by tamoxifenbound estrogen receptor-α and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT. Mol Endocrinol 19, 1543-1554.
5. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, and Schiff R (2004). Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96, 926-935.
6. Zhao H, Ou-Yang F, Chen IF, Hou MF, Yuan SS, Chang HL, Lee YC, Plattner R, Waltz SE, Ho SM, et al. (2010). Enhanced resistance to tamoxifen by the c-ABL proto-oncogene in breast cancer. Neoplasia 12, 214-223.
7. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, et al. (1995). Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270, 1491-1494.
8. Wen J, Li R, Lu Y, and Shupnik MA (2009). Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions. Oncogene 28, 575-586.
9. Arpino G, Gutierrez C, Weiss H, Rimawi M, Massarweh S, Bharwani L, De Placido S, Osborne CK, and Schiff R (2007). Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst 99, 694-705.
10. Meijer D, van Agthoven T, Bosma PT, Nooter K, and Dorssers LC (2006). Functional screen for genes responsible for tamoxifen resistance in human breast cancer cells. Mol Cancer Res 4, 379-386.
11. Wagh PK, Peace BE, and Waltz SE (2008). Met-related receptor tyrosine kinase ron in tumor growth and metastasis. Adv Cancer Res 100, 1-33.
12. Peace BE, Hughes MJ, Degen SJ, and Waltz SE (2001). Point mutations and overexpression of ron induce transformation, tumor formation, and metastasis. Oncogene 20, 6142-6151.
13. Zinser GM, Leonis MA, Toney K, Pathrose P, Thobe M, Kader SA, Peace BE, Beauman SR, Collins MH, and Waltz SE (2006). Mammary-specific ron receptor overexpression induces highly metastatic mammary tumors associated with β-catenin activation. Cancer Res 66, 11967-11974.
14. Chen YQ, Zhou YQ, Fisher JH, and Wang MH (2002). Targeted expression of the receptor tyrosine kinase RON in distal lung epithelial cells results in multiple tumor formation: oncogenic potential of RON in vivo. Oncogene 21, 6382-6386.
15. O'Toole JM, Rabenau KE, Burns K, Lu D, Mangalampalli V, Balderes P, Covino N, Bassi R, Prewett M, Gottfredsen KJ, et al. (2006). Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member. Cancer Res 66, 9162-9170.
16. Maggiora P, Marchio S, Stella MC, Giai M, Belfiore A, De Bortoli M, Di Renzo MF, Costantino A, Sismondi P, and Comoglio PM (1998). Overexpression of the RON gene in human breast carcinoma. Oncogene 16, 2927-2933.
17. Lee WY, Chen HH, Chow NH, Su WC, Lin PW, and Guo HR (2005). Prognostic significance of co-expression of RON and METreceptors in node-negative breast cancer patients. Clin Cancer Res 11, 2222-2228.
18. Welm AL, Sneddon JB, Taylor C, Nuyten DS, van de Vijver MJ, Hasegawa BH, and Bishop JM (2007). The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proc Natl Acad Sci USA 104, 7570-7575.
19. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, et al. (2006). Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98, 262-272.
20. Zheng A, Kallio A, and Harkonen P (2007). Tamoxifen-induced rapid death of MCF-7 breast cancer cells is mediated via extracellularly signal-regulated kinase signaling and can be abrogated by estrogen. Endocrinology 148, 2764-2777.
21. Pink JJ and Jordan VC (1996). Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 56, 2321-2330.
22. Skeel A, Yoshimura T, Showalter SD, Tanaka S, Appella E, and Leonard EJ (1991). Macrophage stimulating protein: purification, partial amino acid sequence, and cellular activity. J Exp Med 173, 1227-1234.
23. Bezerra JA, Witte DP, Aronow BJ, and Degen SJ (1993). Hepatocyte-specific expression of the mouse hepatocyte growth factor-like protein. Hepatology 18, 394-399.
24. Fox EM, Bernaciak TM, Wen J, Weaver AM, Shupnik MA, and Silva CM (2008). Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells. Mol Endocrinol 22, 1781-1796.
25. Peace BE, Hill KJ, Degen SJ, and Waltz SE (2003). Cross-talk between the receptor tyrosine kinases ron and epidermal growth factor receptor. Exp Cell Res 289, 317-325.
26. Wang MH, Wang D, and Chen YQ (2003). Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase. Carcinogenesis 24, 1291-1300.
27. Feres KJ, Ischenko I, and Hayman MJ (2009). The RON receptor tyrosine kinase promotes MSP-independent cell spreading and survival in breast epithelial cells. Oncogene 28, 279-288.
28. Cui Y, Parra I, Zhang M, Hilsenbeck SG, Tsimelzon A, Furukawa T, Horii A, Zhang ZY, Nicholson RI, and Fuqua SA (2006). Elevated expression of mitogenactivated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res 66, 5950-5959.
29. Chen D, Washbrook E, Sarwar N, Bates GJ, Pace PE, Thirunuvakkarasu V, Taylor J, Epstein RJ, Fuller-Pace FV, Egly JM, et al. (2002). Phosphorylation of human estrogen receptor α at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene 21, 4921-4931.
30. Cheng J, Zhang C, and Shapiro DJ (2007). A functional serine 118 phosphorylation site in estrogen receptor-α is required for down-regulation of gene expression by 17β-estradiol and 4-hydroxytamoxifen. Endocrinology 148, 4634-4641.
31. Zwart W, Rondaij M, Jalink K, Sharp ZD, Mancini MA, Neefjes J, and Michalides R (2009). Resistance to antiestrogen arzoxifene is mediated by overexpression of cyclin D1. Mol Endocrinol 23, 1335-1345.
32. Rudas M, Lehnert M, Huynh A, Jakesz R, Singer C, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, et al. (2008). Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy. Clin Cancer Res 14, 1767-1774.
33. Hodges LC, Cook JD, Lobenhofer EK, Li L, Bennett L, Bushel PR, Aldaz CM, Afshari CA, and Walker CL (2003). Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells. Mol Cancer Res 1, 300-311.
34. Banerjee S, Saxena N, Sengupta K, Tawfik O, Mayo MS, and Banerjee SK (2003). WISP-2 gene in human breast cancer: estrogen and progesterone inducible expression and regulation of tumor cell proliferation. Neoplasia 5, 63-73.
35. Sabnis G, Goloubeva O, Jelovac D, Schayowitz A, and Brodie A (2007). Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of longterm estrogen-deprived breast cancer xenografts to antiestrogens. Clin Cancer Res 13, 2751-2757.
36. deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, and Hidalgo M (2004). Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant akt activity. Clin Cancer Res 10, 8059-8067.
37. Fan P, Wang J, Santen RJ, and Yue W (2007). Long-term treatment with tamoxifen facilitates translocation of estrogen receptor α out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. Cancer Res 67, 1352-1360.
38. Lahusen T, Henke RT, Kagan BL, Wellstein A, and Riegel AT (2009). The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer. Breast Cancer Res Treat 116, 225-237.